CapeDx

Helping clinicians select the best treatment

Whole genome analysis is personalising medicine

CapeDx is an end-to-end solution enabling personalised cancer treatment, providing whole genome sequencing (WGS), analysis, annotation and reporting to clinicians.

The service is patient-focused, matching individuals to the latest options in treatment including approved drugs and drugs in clinical trials.

genomiQa helps private and public health systems to provide comprehensive cancer genomics for their patients.

genomiQa can deliver CapeDx as a SaaS (Software as a Service) pipeline to support health service providers and genomics companies to deploy whole genome sequence analysis and variant annotation.

Whole Genome Analysis

the norm, not the exception